BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approach
First evaluated candidate BNT165b1 expresses certain parts of the circumsporozoite protein (CSP)